do not combine dpp-4 inhibitor with glp-1 receptor agonist guideline Mechanisms of dipeptidyl peptidase‐4 (DPP‐4) inhibitors, glucagon‐like DPP4 Inhibitors vs GLP-1 Agonists
Description
In May 2025, Illumina, Inc., and Ovation.io, Inc., announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies
8,9,31,32 These trials provided the first signs of the benefit of GLP-1RAs in HF
Post-treatment with PT302, a long-acting exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinsons disease
Worryingly however, 26.8% of patients had to discontinue the trial due to the severity of side-effects, although it must be noted that this was in part due to the lack of a run-in (A time frame where drug dosage is started from a low dosage and then escalated over time until the highest tolerable dose for the patient is reached) [40]
In Your Brain GLP-1 boosts dopamine, helping with weight management and possibly treating certain addictive behaviors
Another key research frontier is understanding how GLP-1 RAs affect growth, puberty, and psychosocial development
